Last reviewed · How we verify

NCT06572371

Open Versus Laparoscopic Dismembered Pyeloplasty Among Adult Patients With Primary Pelvi-Ureteric Junction Obstruction

Completed NA Last updated 27 August 2024
What this trial tests

NA trial testing Laparoscopic pyeloplasty in Open in 34 participants. Completed in 1 October 2023.

Timeline
1 October 2022
Primary endpoint
1 October 2023
1 October 2023

Quick facts

Lead sponsorTanta University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment34
Start date1 October 2022
Primary completion1 October 2023
Estimated completion1 October 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

18 and older, any sex, with Open or Laparoscopic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To prospectively compare the perioperative, morphological and functional outcomes on short and medium term between laparoscopic (LP) and open pyeloplasty (OP) patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Laparoscopic pyeloplasty

Trials testing the same drug.

Other recruiting trials for Open

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06572371.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing